MeiraGTx Holdings (MGTX) Cost of Revenue (2024 - 2025)

MeiraGTx Holdings (MGTX) reported Cost of Revenue of $476000.0 for Q4 2025, down 95.97% on a YoY basis from $11.8 million in Q4 2024, and up 52.08% quarter-over-quarter from $313000.0 in Q3 2025.

MeiraGTx Holdings (MGTX) Cost of Revenue (2024 - 2025) Analysis & Trends

MeiraGTx Holdings has reported Cost of Revenue for 2 years, with the latest figure at $476000.0 in Q4 2025.

  • For the quarter ending Q4 2025, Cost of Revenue fell 95.97% year-over-year to $476000.0; the trailing twelve-month figure through Dec 2025 stood at $4.8 million (changed N/A YoY), and the FY2025 full-year result was $4.8 million, down 79.64% from the prior year.
  • Cost of Revenue for Q4 2025 stood at $476000.0, up from $313000.0 in the prior quarter.
  • The five-year high for Cost of Revenue was $12.0 million in Q3 2024, with the low at $313000.0 in Q3 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cost of Rev (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 64.20 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - 48,670.00
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 392.80 Mn
9 Abivax 91.96 Bn 91.96 Bn - 2.05 Mn
10 MeiraGTx Holdings 910.47 Mn 844.54 Mn 74.89 Mn 476,000.00

Historic Data

Download Data
DateValue
Dec 31, 2025 476,000.00
Dec 31, 2025 476,000.00
Sep 30, 2025 313,000.00
Sep 30, 2025 313,000.00
Jun 30, 2025 2.68 Mn
Jun 30, 2025 2.68 Mn
Mar 31, 2025 1.38 Mn
Mar 31, 2025 1.38 Mn
Dec 31, 2024 11.81 Mn
Dec 31, 2024 11.81 Mn
Sep 30, 2024 11.99 Mn
Sep 30, 2024 11.99 Mn